|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM351604073 |
| 003 |
DE-627 |
| 005 |
20250304075330.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202210452
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1171.xml
|
| 035 |
|
|
|a (DE-627)NLM351604073
|
| 035 |
|
|
|a (NLM)36649567
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Bo, Yang
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Biomaterial-Based In Situ Cancer Vaccines
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 25.10.2024
|
| 500 |
|
|
|a Date Revised 27.10.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2023 The Authors. Advanced Materials published by Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Cancer immunotherapies have reshaped the paradigm for cancer treatment over the past decade. Among them, therapeutic cancer vaccines that aim to modulate antigen-presenting cells and subsequent T cell priming processes are among the first FDA-approved cancer immunotherapies. However, despite showing benign safety profiles and the capability to generate antigen-specific humoral and cellular responses, cancer vaccines have been limited by the modest therapeutic efficacy, especially for immunologically cold solid tumors. One key challenge lies in the identification of tumor-specific antigens, which involves a costly and lengthy process of tumor cell isolation, DNA/RNA extraction, sequencing, mutation analysis, epitope prediction, peptide synthesis, and antigen screening. To address these issues, in situ cancer vaccines have been actively pursued to generate endogenous antigens directly from tumors and utilize the generated tumor antigens to elicit potent cytotoxic T lymphocyte (CTL) response. Biomaterials-based in situ cancer vaccines, in particular, have achieved significant progress by taking advantage of biomaterials that can synergize antigens and adjuvants, troubleshoot delivery issues, home, and manipulate immune cells in situ. This review will provide an overview of biomaterials-based in situ cancer vaccines, either living or artificial materials, under development or in the clinic, and discuss the design criteria for in situ cancer vaccines
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a Immunotherapy
|
| 650 |
|
4 |
|a biomaterials
|
| 650 |
|
4 |
|a cancer vaccines
|
| 650 |
|
4 |
|a in situ vaccines
|
| 650 |
|
4 |
|a neoantigens
|
| 650 |
|
4 |
|a tumor antigens
|
| 650 |
|
7 |
|a Cancer Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Biocompatible Materials
|2 NLM
|
| 650 |
|
7 |
|a Antigens, Neoplasm
|2 NLM
|
| 700 |
1 |
|
|a Wang, Hua
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 43 vom: 10. Okt., Seite e2210452
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:43
|g day:10
|g month:10
|g pages:e2210452
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202210452
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 43
|b 10
|c 10
|h e2210452
|